Table 3 Expression of IMP3 and IMP2 [clone OTI3F9 and clone EPR6741(B)] in the different tumor types
From: A comprehensive immunohistochemical analysis of IMP2 and IMP3 in 542 cases of ovarian tumors
Marker | HGSC (N = 114) | LGSC (N = 100) | mSBT (N = 41) | EC (N = 54) | CCC (N = 124) | MBT (N = 75)a | MC (N = 34)a |
|---|---|---|---|---|---|---|---|
IMP3 | |||||||
Negative (1–5%) | 38 (33%) | 77 (77%) | 33 (80%) | 33 (61%) | 41 (33%) | 14 (19%) | 6 (18%) |
Any positivity (> 5%) | 76 (67%) | 23 (23%) | 8 (20%) | 21 (39%) | 83 (67%) | 61 (81%) | 28 (82%) |
Positivity (> 5–10%) | 5 (4%) | 11 (11%) | 3 (7.5%) | 2 (4%) | 4 (3%) | 2 (3%) | 1 (3%) |
Positivity (> 10–50%) | 23 (20%) | 8 (8%) | 2 (5%) | 3 (5%) | 27 (22%) | 15 (20%) | 6 (17%) |
Positivity (> 50–100%) | 48 (42%) | 4 (4%) | 3 (7.5%) | 16 (30%) | 52 (42%) | 44 (58%) | 21 (62%) |
IMP2 (clone OTI3F9) | |||||||
Negative (1–5%) | 2 (2%) | 2 (2%) | 0 (0%) | 5 (9%) | 15 (12%) | 3 (4%) | 1 (3%) |
Any positivity (> 5%) | 112 (98%) | 98 (98%) | 41 (100%) | 49 (91%) | 109 (88%) | 70 (96%) | 31 (97%) |
Positivity (> 5–10%) | 1 (1%) | 2 (2%) | 0 (0%) | 1 (2%) | 3 (2%) | 0 (0%) | 1 (3%) |
Positivity (> 10–50%) | 4 (3%) | 8 (8%) | 0 (0%) | 7 (13%) | 12 (10%) | 1 (1%) | 4 (13%) |
Positivity (> 50–100%) | 107 (94%) | 88 (88%) | 41 (100%) | 41 (76%) | 94 (76%) | 69 (95%) | 26 (81%) |
IMP2_clone EPR6741(B) | |||||||
Negative (1–5%) | 0 (0%) | 2 (2%) | 0 (0%) | 13 (24%) | 11 (9%) | 3 (4%) | 3 (9%) |
Any positivity (> 5%) | 114 (100%) | 98 (98%) | 41 (100%) | 41 (76%) | 113 (91%) | 70 (96%) | 29 (91%) |
Positivity (> 5–10%) | 1 (1%) | 2 (2%) | 0 (0%) | 0 (0%) | 2 (2%) | 0 (0%) | 1 (3%) |
Positivity (> 10–50%) | 9 (8%) | 7 (7%) | 0 (0%) | 10 (19%) | 4 (3%) | 6 (8%) | 3 (9%) |
Positivity (> 50–100%) | 104 (91%) | 89 (89%) | 41 (41%) | 31 (57%) | 107 (86%) | 64 (88%) | 25 (78%) |